Mechanism of Action
PTH1R Signaling
PTH1R is a class B GPCR that couples to Gs (primary) and Gq, activating adenylyl cyclase (cAMP/PKA) and phospholipase C pathways. In bone, cAMP-PKA activation in osteoblasts upregulates RANKL, which stimulates osteoclast differentiation and bone resorption. Simultaneously, PTH increases osteoblast survival and anabolic signaling when exposure is intermittent. In the kidney, PTH inhibits phosphate reabsorption in proximal tubules (phosphaturia) and increases calcium reabsorption in distal tubules.
Pulsatile vs Continuous Exposure
The pharmacological principle underlying PTH osteoporosis therapy: intermittent once-daily SC injection produces transient PTH1R stimulation that activates anabolic pathways in osteoblasts before osteoclastic responses fully develop, resulting in net bone formation. Continuous PTH exposure (as in hyperparathyroidism or continuous IV infusion) shifts to net bone resorption and hypercalcemia. This pulsatile anabolic window is the same principle underlying physiological PTH pulsatility.
Research Summary
Hypoparathyroidism (Natpara)
FDA ApprovedREPLACE Phase 3 trial: Natpara 50-100 mcg daily reduced calcitriol supplementation requirements by >50% in 53% of patients vs 2% placebo, while maintaining normo- or near-normocalcemia. FDA approved 2015 for chronic management of hypocalcemia in hypoparathyroidism. REMS program required due to osteosarcoma risk (same as teriparatide). Natpara is the only hormone replacement therapy for hypoparathyroidism.
Osteoporosis (PTH 1-34 Teriparatide)
FDA Approved (Teriparatide)The N-terminal PTH 1-34 fragment (teriparatide, Forteo) was FDA-approved 2002 for severe osteoporosis. Full-length PTH 1-84 shows equivalent anabolic effects. Both stimulate osteoblast activity and new bone matrix formation at trabecular and cortical sites. PTH-based anabolic therapy is reserved for high-fracture-risk patients due to osteosarcoma risk and treatment duration limits (2 years maximum).
Calculate your Parathyroid Hormone dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Hypoparathyroidism (Natpara) | 50 mcg SC once daily initially; titrate to 25 or 100 mcg based on calcium levels | Once daily, same time each day | Subcutaneous (thigh) |
| Calcium homeostasis research | IV PTH 1-84 at 0.5-2 mcg/kg for acute calcium mobilization studies | Single research dose | Intravenous |
Monitor serum calcium 3-7 days after each dose change. Limit cumulative PTH1R agonist therapy to 2 years due to osteosarcoma risk; same caution as teriparatide. Natpara contraindicated with teriparatide.
Interactions
Safety Profile
Common: hypercalcemia, hypercalciuria, headache, nausea, paresthesias. Monitor serum calcium closely, especially within 72 hours of dose changes. Serious: osteosarcoma (rat carcinogenicity data; black box warning; REMS required); contraindicated in patients at elevated osteosarcoma risk (Paget disease, prior radiation, bone metastases, open epiphyses). Hypercalcemia management requires dose reduction or calcium supplement reduction. Duration of use limited to 2 years (same as teriparatide) due to theoretical cumulative bone tumor risk.
References
- [1]Mannstadt M, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013;1(4):275-283.
- [2]Potts JT Jr. Parathyroid hormone: past and present. J Endocrinol. 2005;187(3):311-325.